Ratings Beijing Tong Ren Tang Chinese Medicine Company Limited Deutsche Boerse AG
Equities
TQR
HK0000145638
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.05 EUR | 0.00% | -0.94% | -24.46% |
Jun. 07 | Beijing Tong Ren Tang Chinese Medicine Company Limited Approves Final Dividend for the Year Ended December 31, 2023 | CI |
May. 13 | Tong Ren Tang Chinese Medicine Appoints CEO | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- With a P/E ratio at 11.59 for the current year and 8.95 for next year, earnings multiples are highly attractive compared with competitors.
- The company is one of the best yield companies with high dividend expectations.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-24.46% | 957M | - | ||
+56.89% | 809B | C+ | ||
+39.52% | 624B | B | ||
-6.55% | 351B | C+ | ||
+7.92% | 289B | C+ | ||
+13.74% | 240B | B+ | ||
+13.83% | 220B | B- | ||
-0.49% | 219B | A+ | ||
+7.94% | 166B | C+ | ||
-2.57% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 3613 Stock
- TQR Stock
- Ratings Beijing Tong Ren Tang Chinese Medicine Company Limited